A Clinical Study on the Efficacy and Safety of Adebrelimab Combined with Interventional Therapy in Patients with Pancreatic Cancer Liver Metastases

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600125023

Enrollment

Unknown

Registered

2026-05-20

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer with liver metastases

Interventions

Trial group:Atezolizumab combined with interventional therapy: 1. Transarterial infusion chemotherapy (Oxaliplatin 60 mg/m^2 + Liposomal Irinotecan 50 mg/m^2 + LV 400 mg/m^2 + 5-FU 2400 mg/m^2, Day 1,

2. Atezolizumab 1200 mg, intravenous infusion, q3w (+/-3 days), until disease progression or intolerable toxicity.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 and =3 months; 7. Adequate organ function, including: (1) Hemoglobin (Hb) >=90 g/L; (2) Absolute neutrophil count (ANC) >=1.5 × 10^9/L; (3) Platelet count (PLT) >=50 × 10^9/L; (4) Total bilirubin (TBIL) 60 mL/min; 8. Agreement to use effective contraception during the study period and for 120 days after the last dose, or prior surgical sterilization; 9. Written informed consent signed voluntarily with good protocol compliance anticipated.

Exclusion criteria

Exclusion criteria: 1. Active brain metastases, peritoneal metastases, or bone metastases; 2. Use of immunosuppressive agents within 28 days before first administration; 3. Receipt of antitumor traditional Chinese medicine or immunomodulatory therapy within 4 weeks before first dosing; 4. Severe cardiovascular disease; 5. Severe infection or major surgery within 4 weeks before first administration; 6. Active autoimmune disease or immunodeficiency; 7. Poorly controlled asthma; 8. HIV infection or active hepatitis B/C infection; 9. History of solid organ or hematopoietic stem cell transplantation; 10. Participation in another interventional clinical trial; 11. Known hypersensitivity to the study drug or similar biologics; 12. History of allogeneic organ transplantation; 13. Psychiatric disorders or substance abuse history; 14. Uncontrolled hypertension; 15. Coagulation dysfunction or bleeding tendency; 16. Urine protein >=++ or 24-hour urinary protein >=1.0 g; 17. Any other condition deemed unsuitable for study participation by the investigator.

Design outcomes

Primary

Measure	Time frame
Progression-free survival;	—

Secondary

Measure	Time frame
Overall survival;Objective response rate;Disease control rate;	—

Countries

China

Contacts

Public ContactYang Zhengqiang

National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

yangzq@cicams.ac.cn+86 198 0106 6980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026